Analyst Forecast. According to 14 analysts, the average rating for MRNA stock is "Buy." The month stock price forecast is $, which is an increase. Get Wall Street analysts ratings for Moderna, Inc. (MRNA). Buy or Sell this stock? See what the analysts say. The forecasts range from a low of $ to a high of $ A stock's price target is the price at which analysts consider it fairly valued with respect to. Analyst Ratings of MODERNA INC(NASDAQ:MRNA) stock. Analyst ratings, forecast, price target, upgrades and downgrades. MRNA Forecasts · analyst rating · 1-year stock price forecast.
Moderna Inc's average analyst rating is Buy. Stock Target Advisor's own stock analysis of Moderna Inc is Neutral, which is based on 6 positive signals and 6. Ratings values: · Strong Buy = 5 · Moderate Buy = 4 · Hold = 3 · Moderate Sell = 2 · Strong Sell = 1. See Moderna, Inc. (MRNA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades (MRNA). Follow. Compare. + (+. Ratings Values: ; Strong Buy5 ; Moderate Buy4 ; Hold3 ; Moderate Sell2 ; Strong Sell1. Free Moderna (MRNA) analysis tools, including analyst ratings and target price forecasts, help you make informed investment decisions. Based on short-term price targets offered by 19 analysts, the average price target for Moderna comes to $ The forecasts range from a low of $ to a. Moderna Inc has a consensus price target of $ based on the ratings of 25 analysts. The high is $ issued by Wolfe Research on November 9, 21 analyst ratings ; RBC Capital. Luca Issi. 32% accuracy. 26 / 82 met price target. 4%upside. $ Sector Perform. Downgraded ; RBC Capital. Luca Issi. 32%. We've gathered analysts' opinions on Moderna, Inc. future price: according to them, MRNA price has a max estimate of USD and a min estimate of USD. Analysts' Consensus ; Mean consensus. OUTPERFORM ; Number of Analysts. 25 ; Last Close Price. USD ; Average target price. USD ; Spread / Average Target. +. Analyst Rating and Forecast Moderna is a commercial-stage biotech that was founded in and had its initial public offering i Show More.
See the latest Moderna stock price and MRNA stock rating, related news, valuation, dividends and more to help you make your investing decisions. Based on analysts offering 12 month price targets for MRNA in the last 3 months. The average price target is $ with a high estimate of $ and a low. Moderna (MRNA) has a Smart Score of 3 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. Moderna IncStock, MRNA · Is Moderna stock a Buy, Sell or Hold? Moderna stock has received a consensus rating of hold. · What was the week low for Moderna. Moderna Inc. analyst ratings, historical stock prices, earnings estimates & actuals. MRNA updated stock price target summary. On average, Wall Street analysts predict that Moderna's share price could reach $ by Aug 15, The average Moderna stock price prediction forecasts a. Based on 16 Wall Street analysts who have issued ratings for Moderna in the last 12 months, the stock has a consensus rating of "Hold. Mean consensus. OUTPERFORM ; Number of Analysts. 25 ; Last Close Price. USD ; Average target price. USD ; Spread / Average Target. +%. The average analyst rating for Moderna stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market.
Moderna, Inc. analysts consensus, targets, ratings and recommendations | Wiener Boerse: MRNA | Wiener Boerse. Moderna Inc. research and ratings by Barron's. View MRNA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Find the latest Moderna, Inc. (MRNA) stock quote, history Research Analysis: MRNA. View More. Earnings Per Share. Consensus EPS. Analyst Recommendations. The company's average rating score is , and is based on 7 buy ratings, 8 hold ratings, and 1 sell rating. Amount of Analyst Coverage. Moderna has been the. We've gathered opinions of 26 analysts rating MRNA stock in the past 3 months. Most of them backed up the neutral trend, and after taking into account other.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that. Moderna Inc. · · Partner Center · Your Watchlists · Recently Viewed Tickers · MRNA Overview · Key Data · Performance · Analyst Ratings. Moderna receives Investment Bank Analyst Rating Update. Piper Sandler analysts reiterated an Overweight rating and $ price target on Moderna (NASDAQ:MRNA). Biotechnology · Biotechnology. Market Cap. B. B. 35B. B. Employees. 1, 7, 2, 10, Go Premium to see ratings on MRNA peers. Key Stats · Market CapB · Shares OutM · 10 Day Average VolumeM · Dividend- · Dividend Yield- · Beta · YTD % Change